George Griffith Email and Phone Number

+Led the development and strategy of the world’s first ever self/home administered vaccine (FluMist) from raw concept to FDA filing (now FDA approved). Responsible for all AZ Senior Executive Team Committee reviews and approvals, human factors studies, external partnership assessments, packaging development, initial US launch plan, and Ex-US planning. +Global Commercial Head of Synagis from March 2021 to February 2022 (competition law required separation of role as part of my role as JSC voting member in Sanofi alliance). Led the repatriation of ex-US rights and launch as an AZ product in over 85+ countries which won prestigious AZ BBU Award. +Served as acting Global Project Leader for Flumist/Fluenz from March 2021 to May 2022

Global Commercial lead for the supportive care oncology biosimilars portfolio (Retacrit, Nivestim/Nivestym, and Nyvepria PFS) including commercial development for pegfilgrastim on body injector (OBI) development program.

U.S. marketing lead responsible for overall brand strategy and execution across all channels and segments.

Selected by senior management to serve on Pfizer’s first ever Global Health Team for a one month assignment in India to make strategic recommendations on a key public/private mass vaccination program.

Led the market access strategy, CDC/ACIP planning team (co-led with Medical team), and long range strategy and operating plan for Prevnar.

Led a team of ten sales representatives for specialty products in Philadelphia area.

Selected for international assignment to lead the commercial development strategy and delivery of the global launch plan for Shingrix.

Responsible for U.S. pricing reccomendations, generating payer market insights, developing high-impact reimbursement access strategies, and developing field facing reimbursement solutions in preparation of launches (QIV Flu, Boostrix, and Menhibrix).

Recruited to newly created payer marketing team to support multiple product launches (QIV Flu, Boostrix, and Menhibrix).

Developed and implemented market access strategies and tactics for key vaccine and infectious disease product launches (Zostavax 50-59, Gardasil, Isentress, and Victrelis) focused on removing reimbursement barriers to drive rapid utilization.

Designed and implemented the national roll out of new field force sales incentive compensation metrics across all US business units as part of Merck’s new commercial model.

Responsible for assessing and delivering strategic recommendations for key vaccine business opportunities across brands impacting vaccine commercial model, distribution strategy, market share defense strategies, and contracting/pricing strategies.

Launched two products (Zostavax and Gardasil) and drove sales for entire vaccine portfolio in offices, hospitals, and IDNs. Ranked as one of top sales reps in the country.

Pre-launch market shaping for HPV and Zoster vaccine launches by establishing key relationships with key thought leaders, providers, and local/regional institutions.

Drove sales and market share growth for products across cardiovascular, respiratory, pain, and endocrinology therapeutic areas. Top Performer.